VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury (VALSE)
2026年8月3日 更新者：Jocelyne Bloch、Ecole Polytechnique Fédérale de Lausanne
The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury.
The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL.
The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.
調査の概要
状態
状態
まだ募集していません
条件
条件
介入・治療
介入・治療
詳細な説明
Spinal cord injury (SCI) disrupts communication between the brain and spinal cord below the lesion, often resulting in severe and permanent motor impairments. Despite advances in rehabilitation, recovery of walking remains limited and restoring mobility is consistently identified as a top priority by individuals living with SCI.
Epidural electrical stimulation (EES) of the spinal cord has emerged as a promising approach to restore movement after paralysis. By activating spinal motor circuits below the lesion, EES can enable standing, stepping, and walking in individuals with chronic SCI. ONWARD Medical has developed the ARC-IM spinal stimulation platform, which is currently being evaluated in several clinical studies, including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290).
In the BoxSwitch trial, optimized spatiotemporal EES protocols enabled participants with chronic SCI to perform standing, stepping, and walking movements. Building on these findings, the Think2Go and STIMO-BSI studies integrated the WIMAGINE implantable electrocorticography (ECoG) system developed by Clinatec (CEA, Grenoble, France) with spinal stimulation, creating a brain-spine interface capable of decoding motor intentions and translating them into spinal stimulation. These studies demonstrated that implantable brain-spine interfaces can restore voluntary control of lower-limb movements and support functional walking after severe paralysis.
Although these technologies have shown encouraging results, their use remains largely restricted to specialized rehabilitation settings. In parallel, robotic exoskeletons have been developed to support overground walking in individuals with SCI. The TWIICE exoskeleton is a lightweight and modular system specifically designed for use beyond rehabilitation centers and may complement spinal stimulation by providing functional support during walking.
In this study, the investigators will evaluate the preliminary safety and feasibility of the VALSE system, which combines the ARC-IM spinal cord stimulation platform with the TWIICE robotic exoskeleton in individuals with chronic traumatic SCI. Participants will be recruited from ongoing clinical studies at Lausanne University Hospital (CHUV), including BoxSwitch (NCT05942339), Think2Go (NCT06243952), and STIMO-BSI (NCT04632290), after completion of the relevant study phases.
As an early feasibility investigation, the study aims to generate preliminary safety and usability data on the combined use of spinal neuromodulation and robotic assistance during mobility tasks. The results will support the development of future neuroprosthetic solutions designed to improve walking ability, independence, and quality of life for people living with SCI.
研究の種類
研究の種類
介入
入学 (推定)
入学
12
段階
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
研究連絡先
- 名前：Henri Lorach, PhD
- 電話番号：+41 77 495 50 48
- メール：henri.lorach@epfl.ch
研究連絡先のバックアップ
- 名前：Jocelyne Bloch, Prof.
- 電話番号：+41 79 556 29 51
- メール：jocelyne.bloch@chuv.ch
研究場所
-
-
Canton of Vaud
-
Lausanne、Canton of Vaud、スイス、1005
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
コンタクト：
- Jocelyne Bloch
- 電話番号：0795568979
- メール：Jocelyne.bloch@chuv.ch
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Currently enrolled participants who have completed the relevant phase of their parent study at CHUV: BoxSwitch (NCT05942339, after the optimisation phase), Think2Go (NCT06243952, after the rehabilitation phase, or STIMO-BSI (NCT04632290, after the calibration and training phase of the optional extension with system upgrade),
- Must have a functional neuromodulation system,
- Must be at least 18 years old,
- Must be suffering from non-progressive traumatic spinal cord injury, sustained at least 12 months before signing the consent form,
- Must weigh less than 100 kg,
- Must have a standing height between 160 and 190 cm,
- Must be able to grasp and lift bilateral crutches in a seated position,
- Must have stable medical, physical and psychological condition as considered by the investigator,
- Must be able to understand and interact with the study team in French or English,
- Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments,
- Must provide Informed Consent as documented by signature prior to any study-related procedures.
Exclusion Criteria:
- Must not be diagnosed with severe osteoporosis/penia:
Dual Energy X-ray Absorptiometry (DEXA) results indicating a t-score below -3.5 at either the femoral neck or the total proximal femur.
Dual Energy X-ray Absorptiometry (DEXA) results indicating a bone mineral density (BMD) < 0.60 gm/cm2 at any knee region (distal femur, proximal tibia)
- Must not have deep vein thrombosis in lower extremities within the past 6 months.
- Must not have experienced lower extremity fractures within the last two years.
- Must not have current pressure ulcer of the arms, trunk, pelvic area, or lower extremities
- Must not present with a flexion contracture >15° at the hip or knee
- Must not have severe concurrent medical conditions that contraindicate moderate to intense exercise (e.g., uncontrolled hypertension, coronary artery disease, congestive heart failure).
- Must not have heterotopic ossification that impairs joint mobility
- Must not be implanted with a life-supporting medical device (devices implanted in the parent study are not considered life-supporting),
- Must not be pregnant,
- Must not be the investigator himself, his/her family members, employees, or other dependent persons.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
アーム数
1
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：All participant
All participants receive the same intervention. Each participant will complete 3 predefined study periods within 1 year of enrolment. Each study period lasts 3 weeks, and study periods are separated by a minimum interval of 1 month. |
Participants will use the VALSE system, which combines the TWIICE Rise 1.0 robotic exoskeleton with epidural electrical stimulation (EES) delivered through previously implanted neuromodulation systems.
The system is intended to support upright mobility and overground walking in individuals with chronic spinal cord injury (SCI) who are currently enrolled in, or have completed key phases of, neuromodulation clinical trials at CHUV, including Think2Go (NCT06243952), STIMO-BSI (NCT04632290), and BoxSwitch (NCT05942339).
The TWIICE exoskeleton provides robotic gait assistance, while EES facilitates activation of spinal motor circuits below the level of injury.
Exoskeleton movements are initiated and controlled through participant-generated inputs, including finger-click commands and, where applicable, brain-derived control signals from previously implanted brain-spine interface systems.
The VALSE system is used in supervised clinical and controlled real-world.
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preliminary safety
時間枠：From enrollment until the end of study timepoint, up to 1 year after enrollment.
|
Occurrence of Serious Adverse Events (SAE) and Adverse Events (AE) that are deemed related or possibly related to the procedure or to the TWIICE exoskeleton in combination with the neuromodulation therapies (VALSE system)
|
From enrollment until the end of study timepoint, up to 1 year after enrollment.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of the experimental session conditions
時間枠：At each in-clinic training session during the three study periods, up to 1 year after enrollment.
|
Location and type of ground walked on.
|
At each in-clinic training session during the three study periods, up to 1 year after enrollment.
|
|
Number of steps
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total number of steps recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Step frequency
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Average step frequency (cadence) recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Mid-stride pauses
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Number of mid-stride pauses recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Distance walked
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total distance walked recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Walking time
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total walking time recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Standing time
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Total standing time recorded by the exoskeleton during each experimental (EX) session.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Kinematic gait parameters
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Kinematic gait parameters recorded during overground walking and functional locomotor tasks (change of walking speed, stepping over and turn around obstacles, climb stairs, walk with cognitive load (e.g., counting backward by threes)) using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Electromyographic (EMG) activity
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Muscle activation patterns recorded by surface electromyography during overground walking and functional locomotor tasks while using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Brain-computer interface (BCI) performance
時間枠：At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
Brain-computer interface performance metrics recorded during overground walking and functional locomotor tasks while using the VALSE system.
|
At each experimental (EX) session during the three study periods, up to 1 year after enrollment.
|
|
Donning and Doffing Time
時間枠：At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
Assessment of the time it takes to put on and take off the system.
Donning time is recorded from the start of preparation until the participant is fully ready for ambulation.
Doffing time is recorded from the start of removal until the participant is fully disengaged from the system.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
Level of Assistance (LOA)
時間枠：At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
Assessment to evaluates the amount of physical support required by the participant during walking and mobility activities with the device.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
System Usability Scale (SUS)
時間枠：At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
A validated 10-item questionnaire measuring usability across multiple domains.
Scores range from 0-100, with higher values indicating greater usability.
Will be filled in by participants and physiotherapists.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
|
ASA Task Load Index (NASA-TLX)
時間枠：At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
A 6-dimension tool assessing perceived workload (mental demand, physical demand, temporal demand, performance, effort, frustration).
Will be filled in by participants and physiotherapists.
|
At the last experimental (EX) session of each of the three study periods, up to 1 year after enrollment.
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
捜査官
- 主任研究者：Jocelyne Bloch, Prof.、Centre Hospitalier Universitaire Vaudois (CHUV)
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7.
- Gorgey AS, Gill S, Holman ME, Davis JC, Atri R, Bai O, Goetz L, Lester DL, Trainer R, Lavis TD. The feasibility of using exoskeletal-assisted walking with epidural stimulation: a case report study. Ann Clin Transl Neurol. 2020 Feb;7(2):259-265. doi: 10.1002/acn3.50983. Epub 2020 Feb 5.
- Hong E, Gorman PH, Forrest GF, Asselin PK, Knezevic S, Scott W, Wojciehowski SB, Kornfeld S, Spungen AM. Mobility Skills With Exoskeletal-Assisted Walking in Persons With SCI: Results From a Three Center Randomized Clinical Trial. Front Robot AI. 2020 Aug 4;7:93. doi: 10.3389/frobt.2020.00093. eCollection 2020.
- Vouga T, Fasola J, Baud R, Manzoori AR, Pache J, Bouri M. TWIICE One powered exoskeleton: effect of design improvements on usability in daily life as measured by the performance in the CYBATHLON race. J Neuroeng Rehabil. 2022 Jun 27;19(1):63. doi: 10.1186/s12984-022-01028-0.
- Zhang T, Jia Y, Wang N, Chai X, He Q, Cao T, Mu Q, Lan Q, Zhao J, Yang Y. Recent advances in potential mechanisms of epidural spinal cord stimulation for movement disorders. Exp Neurol. 2025 Oct;392:115330. doi: 10.1016/j.expneurol.2025.115330. Epub 2025 Jun 4.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
研究開始
2026年9月15日
一次修了 (推定)
一次修了
2028年5月1日
研究の完了 (推定)
研究の完了
2028年9月1日
試験登録日
最初に提出
最初に提出
2026年6月25日
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
2026年8月3日
最初の投稿 (実際)
最初の投稿
2026年8月4日
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
2026年8月4日
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
2026年8月3日
最終確認日
最終確認日
2026年8月1日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- VALSE
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。